Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

OmniAb (OABI) stock in plain English

Free brief · no signupStart here
OABIPublished Nov 18, 2026
OmniAb Inc
Healthcare · Biotechnology
Licenses transgenic animal platforms and screening software to biotechnology firms developing human antibody drugs.
Assets:
Transgenic animal platformsEngineered rats, mice, and chickens generating human antibodies
300+ partnered programsActive drug development pipelines funded by commercial partners
Emeryville screening facilityCore laboratory housing high-throughput microfluidics and deep sequencing platforms
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

55
OPS ScoreOperating finances
Latest quote
-0.98%$5.03
$733.68M
n/a (loss)
$40.20M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 18, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was OABI. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does OmniAb (OABI) do?

OmniAb Inc (OABI) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Licenses transgenic animal platforms and screening software to biotechnology firms developing human antibody drugs. Licenses genetically engineered rodents and chickens to pharmaceutical companies for human antibody discovery. It is worth $733.68M on the market and sold $40.20M over the last year.

Market cap
$733.68M
P/E ratio
None (reported a loss)
Annual sales
$40.20M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 18, 2026

Brands and businesses behind OABI

  • OmniRat: Genetically engineered rat platform producing fully human antibodies, earning milestone and royalty payments from pharmaceutical partners.
  • OmniChicken: Transgenic chicken platform designed to generate antibodies against human drug targets that mammalian systems cannot easily target.
  • OmniMouse: Genetically modified mouse model that produces diverse human antibodies, earning access fees and downstream royalties from biotech licensees.
  • OmniDeep: Computational and microfluidics screening platform that analyzes millions of single antibody-producing cells for biopharma clients.

OABI’s flags, in plain English

Each flag is a number from OmniAb’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.

Stupid Cash

Can pay this year's bills 4.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 7% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Insiders Hold

Insiders own 18.5% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Burning Cash

Losing money, profit margin of -108.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about OABI

How big is OmniAb?

OmniAb’s market cap is $733.68M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $40.20M: what customers paid the company over the last year, before any costs.

What is OABI’s P/E ratio?

OABI has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with OABI?

Revenue depends heavily on the clinical trial success and development budgets of external pharmaceutical partners. That is one risk on OmniAb’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From OmniAb’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. OABI’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card